MoonLake Immunotherapeutics Price Target Increased by 35.37% to $30.19: Analysts Boost Estimates

MoonLake Immunotherapeutics' (MLTX) average one-year price target has been revised to $30.19, an increase of 35.37% from the prior estimate of $22.30. The price target is based on an average of many targets provided by analysts. The put/call ratio of MLTX is 0.16, indicating a bullish outlook. 175 funds or institutions are reporting positions in MLTX, with Bvf holding 19,751K shares representing 27.54% ownership of the company.